Works matching IS 19450877 AND DT 2017 AND VI 10 AND IP 462
Results: 4
Targeting TNFR2, an immune checkpoint stimulator and oncoprotein, is a promising treatment for cancer.
- Published in:
- Science Signaling, 2017, v. 10, n. 462, p. 13, doi. 10.1126/scisignal.aal2328
- By:
- Publication type:
- Article
The neuropilin 2 isoform NRP2b uniquely supports TGFβ-mediated progression in lung cancer.
- Published in:
- Science Signaling, 2017, v. 10, n. 462, p. 1, doi. 10.1126/scisignal.aag0528
- By:
- Publication type:
- Article
Targeting TNFR2 with antagonistic antibodies inhibits proliferation of ovarian cancer cells and tumor-associated T<sub>regs</sub>.
- Published in:
- Science Signaling, 2017, v. 10, n. 462, p. 1, doi. 10.1126/scisignal.aaf8608
- By:
- Publication type:
- Article
De novo phosphorylation and conformational opening of the tyrosine kinase Lck act in concert to initiate T cell receptor signaling.
- Published in:
- Science Signaling, 2017, v. 10, n. 462, p. 1, doi. 10.1126/scisignal.aaf4736
- By:
- Publication type:
- Article